Retatrutide vs. CagriSema: the next-generation showdown

Retatrutide is one peptide that activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP drive appetite suppression and improved insulin handling; glucagon-receptor activation appears to raise resting energy expenditure and mobilize hepatic fat. It pushes on both the "calories in" and "calories out" sides of the equation. [1]

CagriSema combines two separate drugs in a single weekly injection. Semaglutide supplies the GLP-1 agonism. Cagrilintide is a long-acting analogue of amylin, a hormone co-secreted with insulin that promotes satiety via brainstem pathways, slows gastric emptying, and — notably — suppresses glucagon secretion after meals. [2]

That last point is the fascinating divergence: retatrutide activates the glucagon receptor while CagriSema's amylin component tamps glucagon down. Both strategies produce class-leading weight loss, which suggests the field has not converged on a single optimal biology.

In retatrutide's Phase 2 obesity trial, the 12 mg dose produced an average of 24.2% body-weight loss at 48 weeks, vs. about 2% on placebo. [1]

In CagriSema's Phase 3 REDEFINE-1 trial, the combination produced an average of roughly 22.7% body-weight loss at 68 weeks in the analysis of participants who stayed on treatment, vs. about 2.3% on placebo. In the broader analysis including participants who discontinued, the figure was around 20%. [2]

Reading those numbers responsibly: retatrutide's figure comes from a smaller, shorter Phase 2 trial, and some attenuation in Phase 3 would be consistent with the pattern seen across this class. CagriSema's figures come from a large Phase 3 program, but span a roughly three-point range depending on how discontinuations are handled. Until a head-to-head trial exists — none is planned — any claim that one is definitively "stronger" overstates the evidence.

In REDEFINE-1, the most common adverse events with CagriSema were gastrointestinal — nausea, vomiting, constipation, and diarrhea — mostly mild-to-moderate and concentrated during dose escalation, with discontinuation rates similar to other drugs in the class. [2]

Retatrutide's GI profile looks similar, but its trials also recorded a small, dose-dependent increase in resting heart rate — typically a few beats per minute — presumed to relate to glucagon-receptor activity. [1] Long-term cardiovascular safety for both drugs will be established by dedicated outcomes trials, which for both are still pending.

Retatrutide was studied in Phase 2 at maintenance doses up to 12 mg once weekly, titrated in four-week steps. CagriSema is a fixed-dose co-formulation of cagrilintide 2.4 mg with semaglutide 2.4 mg, also injected once weekly after a gradual escalation period. [3]

The co-formulation approach gives Novo Nordisk two independent dose dials during development but locks the ratio in the final product. Retatrutide's single-molecule design is simpler to manufacture and titrate, at the cost of fixing the relative activity at its three receptors by chemistry.

Novo Nordisk built the modern obesity-drug market with semaglutide, then watched Lilly's tirzepatide overtake it on efficacy. CagriSema is Novo's answer: leverage its semaglutide base and add amylin to close the gap. Retatrutide is Lilly's bid to extend its lead beyond tirzepatide before Novo catches up.

With efficacy this close, the commercial winner will likely be decided by factors other than the headline number: tolerability at maintenance dose, manufacturing scale-up, pricing and access programs, the breadth of approved indications (type 2 diabetes, cardiovascular outcomes, sleep apnea, liver disease), and whichever reaches pharmacy shelves first. Both companies also have oral candidates in development that could reshape the rivalry again.

If your frame is "which future drug produces the most weight loss," the honest answer is that the current evidence cannot separate them. Retatrutide's Phase 2 number is nominally higher; CagriSema's Phase 3 evidence base is larger and more mature.

Both remain investigational. Any product sold online under either name is unregulated and unverified. When these drugs reach the market, the choice between them will belong with a clinician who knows your history. This page is informational and is not medical advice.